Second infection with a different hepatitis C virus genotype in a intravenous drug user during interferon therapy

Gut

Volumn 52, Issue 6, 2003, Pages 900-902

  Asselah, T ^a,b   Vidaud, D ^b   Doloy, A ^b   Boyer, N ^a   Martinot, M ^a   Vidaud, M ^b   Valla, D ^a   Marcellin, P ^a  

^a INSERM   (France)

^b BEAUJON HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; HEPATITIS C ANTIBODY; INTERFERON; VIRUS RNA;

ACUTE HEPATITIS; ADULT; ARTICLE; CASE REPORT; CHRONIC HEPATITIS; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INTRAVENOUS DRUG ABUSE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SUPERINFECTION; VIRUS LOAD; VIRUS TYPING;

ACUTE DISEASE; ADULT; ANTIVIRAL AGENTS; FEMALE; HEPACIVIRUS; HEPATITIS C; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; RECURRENCE; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 0037508838     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.52.6.900     Document Type: Article

References (14)

1. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001;345:41-52.
2. Serfaty MA, Lawrie A, Smith B, et al. Risk factors and medical follow up of drug users tested for hepatitis C - can the risk of transmission be reduced? Drug Alcohol Rev 1997;16:339-47.
3. Simmonds P, Holmes EC, Cha TA, et al. Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. J Gen Virol 1993;74:2391-9.
4. Farci P, Alter HJ, Govindarajan S, et al. Lack of protective immunity against reinfection with hepatitis C virus. Science 1992;258:135-40.
5. Lai ME, Mazzoleni AP, Argiolu F, et al. Hepatitis C virus in multiple episodes of acute hepatitis in polytransfused thalassaemic children. Lancet 1994;343:388-90.
6. Payen JL, Izopet J, Barange K, et al. Hepatitis C virus reinfection after an intravenous drug injection. Gastroenterol Clin Biol 1998;22:469-70.
7. Proust B, Dubois F, Bacq Y, et al. Two successive hepatitis C virus infections in an intravenous drug user. J Clin Microbiol 2000;38:3125-7.
8. Mehta SH, Cox A, Hoover DR, et al. Protection against persistence of hepatitis C. Lancet 2002;359:1478-83.
9. Stuyver L, Rossau R, Wyseur A, et al. Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay. J Gen Virol 1993;74:1093-102.
10. Villano SA, Vlahov D, Nelson KE, et al. Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. Hepatology 1999;29:908-14.
11. EASL International Consensus Conference on Hepatitis C. Paris, 26-27 February 1999. Consensus statement. J Hepatol 1999;31 (suppl 1):3-8.
12. Jaeckel E, Cornberg M, Wedemeyer H, et al. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med 2001;345:1452-7.
13. Grjuner NH, Gerlach TJ, Jung MC, et al. Association of hepatitis C virus-specific CD8+ T cells with viral clearance in acute hepatitis C. J Infect Dis 2000;181:1528-36.
14. Cerny A, Chisari FV. Pathogenesis of chronic hepatitis C: immunological features of hepatic injury and viral persistence. Hepatology 1999;30:595-601.